warm autoimmune hemolytic anemia

warm autoimmune hemolytic anemia is a form of autoimmune hemolytic anemia characterized by the production of autoantibodies, primarily of the IgG class, that bind to red blood cell surface antigens at body temperature, leading to their premature destruction. It is the most common type of autoimmune hemolytic anemia, accounting for approximately 70-80% of adult cases. The condition can be idiopathic or secondary to underlying disorders such as lymphoproliferative diseases, autoimmune disorders, or certain medications. Diagnosis hinges on laboratory confirmation of antibody-mediated hemolysis, most notably a positive direct antiglobulin test.

Pathophysiology

The fundamental mechanism involves the production of pathogenic autoantibodies, typically polyclonal IgG antibodies, directed against antigens on the erythrocyte membrane, most commonly against the Rh blood group system. These antibodies bind optimally at 37°C, coating the red cells. The Fc portion of the bound IgG is then recognized by Fc gamma receptors on macrophages, primarily in the spleen, leading to partial phagocytosis and spherocyte formation, a process known as extravascular hemolysis. Less commonly, complement system activation can occur, leading to intravascular hemolysis. The underlying immune dysregulation is often linked to a loss of T cell tolerance and aberrant B cell activation, frequently in the context of conditions like Chronic lymphocytic leukemia or Systemic lupus erythematosus.

Clinical presentation

Patients typically present with signs and symptoms of anemia and jaundice due to the accelerated breakdown of hemoglobin. Common features include profound fatigue, dyspnea, palpitations, and pallor. Jaundice and scleral icterus are often noted on physical examination. Splenomegaly may be present due to reticuloendothelial system hyperplasia. The onset can be insidious or acute, with severe cases potentially presenting as a hemolytic crisis with hemoglobinuria, back pain, and symptoms of hypovolemic shock. The clinical picture is often complicated by the features of any associated underlying disease, such as lymphadenopathy in Non-Hodgkin lymphoma.

Diagnosis

Diagnosis requires a combination of clinical suspicion and confirmatory laboratory tests. Key initial findings on a complete blood count include normocytic anemia, often with an elevated reticulocyte count and a low haptoglobin level. Examination of a peripheral blood smear may reveal spherocytes, polychromasia, and occasionally nucleated red blood cells. The cornerstone of diagnosis is a positive direct antiglobulin test, specifically for IgG and sometimes C3d. Further serological testing, often performed in a blood bank or immunohematology reference laboratory, can identify the specificity of the antibody. It is critical to investigate for secondary causes, which may involve imaging studies like computed tomography and tests for antinuclear antibodies.

Treatment

First-line therapy for primary warm autoimmune hemolytic anemia is administration of corticosteroids, such as prednisone, which suppress antibody production and macrophage function. For patients who are steroid-refractory, steroid-dependent, or intolerant, the anti-CD20 monoclonal antibody rituximab is a standard second-line agent. Splenectomy remains an effective option, particularly for those who fail or cannot receive rituximab, by removing a major site of red blood cell destruction and autoantibody production. Other immunosuppressive drugs used include azathioprine, cyclophosphamide, and mycophenolate mofetil. In severe, refractory cases, hematopoietic stem cell transplantation may be considered. Management of acute severe hemolysis may require blood transfusion, though crossmatching can be challenging.

Prognosis

The prognosis varies widely and is heavily influenced by whether the condition is idiopathic or secondary. Idiopathic cases often respond well to initial therapy, though relapses are common, and many patients require long-term management. Secondary warm autoimmune hemolytic anemia generally carries a prognosis tied to the underlying disease, such as Chronic lymphocytic leukemia or Systemic lupus erythematosus. Complications like venous thromboembolism and cardiac failure due to severe anemia can impact morbidity and mortality. With modern treatments including rituximab, overall outcomes have improved, but the disease can follow a chronic, relapsing course requiring ongoing hematological surveillance. Category:Autoimmune diseases Category:Hematology Category:Immune system